DC-CIK Cell for Immunotherapy Development

By offering our clients consultative services that are founded upon the industry solution, we can be your go-to partner for the entire journey of your DC-CIK cell therapy. Creative Biolabs offers a range of risk assessment, project consulting, as well as data verification services to satisfy any specific requirement at the most competitive price. Currently, with our extensive experience and advanced platform, we have won a good reputation among our worldwide customers for successfully accomplishing numerous challenging projects in this field.

Introduction to DC-CIK Cell Therapy

Dendritic cells (DCs) play a critical role in presenting antigens to T cells. A number of DC cell-based therapy and vaccines have been broadly generated to treating a wide variety of human tumors. Meanwhile, cytokine-induced killer (CIK) cells have also been considered as key effector cells, which are cultured by lymphocytes with the CD3 monoclonal antibody, Interleukin (IL), as well as interferon (IFN). Previous studies have demonstrated that the anti-tumor activity of CIK cells and DC cells have been identified in different kinds of tumor models. Furthermore, several clinical trials have also revealed that CIK cells and DC cells can provide a safe, highly effective cell therapy in a large scale of patients. According to these data, a new combination therapy based on DC-CIK cells has been generated to trigger a stronger anti-tumor effect in various tumor cells, such as adenocarcinoma cell lines. Among them, DC-CIK cell therapy with chemotherapy can be the best method to improve the overall survival (OS) and disease-free survival (DFS) of patients.

Overall survival (OS) and Progression-free survival (PFS) for the different DC-CIK treatment groups. Fig.1 Overall survival (OS) and Progression-free survival (PFS) for the different DC-CIK treatment groups. (Qiao, 2019)

Our Services for DC-CIK Cell Therapy

Creative Biolabs has established a comprehensive project evaluation platform, from fully understanding and identifying your requirement to commercial-stage manufacturing. With years of experience, we are capable of optimizing the development workflows to avoid data variability, reduce overall cost, and shorten development time. For instance, the risk assessment service will help you define the potential risks and generate suitable assays. The manufacturing assessment service offers an extensive evaluation of a DC-CIK cell therapy process to achieve the objectives.

What Can We Do?

As a leader in the field of cell therapy development, Creative Biolabs has built a team of experienced scientists with facilities and processes designed specifically to provide the best-customized services to assess the design, risk, safety, and feasibility of your projects. We have successfully completed a series of challenges in the past years. In particular, we have established an advanced DC-CIK cell therapy platform that enables us to help build and establish a long-term vision with commercialization in mind. If you are interested in our services, please contact us or send us an inquiry.


  1. Qiao, G.; et al. Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. Clin Cancer Res. 2019, 25(5): 1494-1504.
For Research Use Only
Let's Get Started
Contact Us

Follow us on
Copyright © 2024 Creative Biolabs. All Rights Reserved.